Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1990 1
1993 1
1995 1
1998 1
1999 1
2000 2
2002 1
2003 2
2006 2
2012 2
2014 2
2015 4
2016 1
2017 1
2018 2
2020 2
2021 2
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Evolving Complexity in Hemophilia Management.
Croteau SE. Croteau SE. Pediatr Clin North Am. 2018 Jun;65(3):407-425. doi: 10.1016/j.pcl.2018.01.004. Pediatr Clin North Am. 2018. PMID: 29803274 Review.
Rapid expansion of therapeutic options have increased the complexity of hemophilia care. Previously, on-demand therapy aimed to reduce morbidity and early mortality; however, now aggressive prophylaxis, particularly in children, encourages an active …
Rapid expansion of therapeutic options have increased the complexity of hemophilia care. Previously, on-demand therapy …
Pain assessment and management in Italian Haemophilia Centres.
Di Minno MND, Santoro C, Corcione A, Di Minno G, Martinelli M, Mancuso ME, Acone B, Molinari AC, Passeri EV, Rocino A, Santoro RC, Tagliaferri A, Mattia C; HAEMODOL Study Group (Appendix 1). Di Minno MND, et al. Blood Transfus. 2021 Jul;19(4):335-342. doi: 10.2450/2020.0085-20. Epub 2020 Nov 27. Blood Transfus. 2021. PMID: 33263519 Free PMC article.
BACKGROUND: Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the severity of arthropathy in persons with haemophilia (PWH), some develop degenerative joint changes, associated with significant pain. ...The lac …
BACKGROUND: Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the seve …
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G, Coppens M, Pipe SW. Castaman G, et al. Expert Rev Hematol. 2023 Jul-Dec;16(12):919-932. doi: 10.1080/17474086.2023.2276206. Epub 2023 Dec 18. Expert Rev Hematol. 2023. PMID: 37882214 Review.
INTRODUCTION: Etranacogene dezaparvovec is the first gene therapy approved for treatment of adults with severe and moderately severe hemophilia B. ...Etranacogene dezaparvovec enables most patients to reach stable factor IX (FIX) levels after a single intrave …
INTRODUCTION: Etranacogene dezaparvovec is the first gene therapy approved for treatment of adults with severe and moderately severe …
Prevention and treatment of myeloma bone disease.
Terpos E, Kastritis E, Dimopoulos MA. Terpos E, et al. Curr Hematol Malig Rep. 2012 Dec;7(4):249-57. doi: 10.1007/s11899-012-0135-0. Curr Hematol Malig Rep. 2012. PMID: 22941027 Review.
Zoledronic acid and pamidronate have shown similar efficacy in reducing SREs in a randomized study in the conventional chemotherapy era. However, in a recent study (the Myeloma-IX trial of the UK Medical Research Council, MRC), zoledronic acid was found to be superi …
Zoledronic acid and pamidronate have shown similar efficacy in reducing SREs in a randomized study in the conventional chemotherapy e …
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
Mancuso ME, Mahlangu JN, Pipe SW. Mancuso ME, et al. Lancet. 2021 Feb 13;397(10274):630-640. doi: 10.1016/S0140-6736(20)32722-7. Epub 2021 Jan 15. Lancet. 2021. PMID: 33460559 Review.
Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding disorders. Replacement therapy has been the cornerstone of the management of haemophilia, aiming to reduce the mortality and morbidity of chroni …
Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding disorders. Replace …
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.
Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez-Merchan C, Spannagl M, Valentino LA, Young G, Steinitz-Trost KN, Gringeri A. Iorio A, et al. Haemophilia. 2017 May;23(3):e170-e179. doi: 10.1111/hae.13215. Epub 2017 Mar 26. Haemophilia. 2017. PMID: 28345268
BACKGROUND: Prophylactic replacement with factor concentrate is the optimal treatment for persons with severe haemophilia to avoid or minimize bleeding. This ultimately prevents or reduces joint disease and improves life expectancy and quality of life towards values …
BACKGROUND: Prophylactic replacement with factor concentrate is the optimal treatment for persons with severe haemophilia to avoid or …
New products for the treatment of haemophilia.
Laffan M. Laffan M. Br J Haematol. 2016 Jan;172(1):23-31. doi: 10.1111/bjh.13797. Epub 2015 Oct 12. Br J Haematol. 2016. PMID: 26456702 Free article. Review.
A variety of new molecules addressing these aims are now completing clinical trials and are ready to enter clinical use. First amongst these are modified Factor VIII (FVIII) and Factor IX (FIX) molecules with extended half-lives. ...Other approaches have gene …
A variety of new molecules addressing these aims are now completing clinical trials and are ready to enter clinical use. First amongst these …
American College of Sports Medicine. Position Stand. Physical activity, physical fitness, and hypertension.
[No authors listed] [No authors listed] Med Sci Sports Exerc. 1993 Oct;25(10):i-x. Med Sci Sports Exerc. 1993. PMID: 8231750 Review.
This has led to a search for nonpharmacological therapies, such as exercise training, for these individuals. The available evidence indicates that endurance exercise training by individuals at high risk for developing hypertension will reduce the rise in blood press …
This has led to a search for nonpharmacological therapies, such as exercise training, for these individuals. The available evidence i …
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Gelbenegger G, et al. Thromb Haemost. 2020 Oct;120(10):1357-1370. doi: 10.1055/s-0040-1714279. Epub 2020 Jul 27. Thromb Haemost. 2020. PMID: 32717759 Free PMC article. Review.
Management of patients with inhibitors is challenging and necessitates immune tolerance induction for inhibitor eradication and the use of bypassing agents (activated prothrombin complex concentrates or recombinant activated factor VII), which are expensive a …
Management of patients with inhibitors is challenging and necessitates immune tolerance induction for inhibitor eradication and the use of b …
The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome.
Vavalle JP, Cohen MG. Vavalle JP, et al. Future Cardiol. 2012 May;8(3):371-82. doi: 10.2217/fca.12.5. Epub 2012 Mar 15. Future Cardiol. 2012. PMID: 22420328 Free PMC article. Review.
A potent anticoagulant that has predictable efficacy, is easily reversible should the clinical need arise, and reduces ischemic events without an increase in bleeding risk would overcome many of the current limitations. Inhibition of factor IX in the coagulat …
A potent anticoagulant that has predictable efficacy, is easily reversible should the clinical need arise, and reduces ischemic event …
30 results